ScoreWhy is Surgical Science Sweden AB ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Net Sales has grown by an annual rate of 56.77% and Operating profit at 44.68%
3
Flat results in Dec 25
- OPERATING CASH FLOW(Y) Lowest at SEK 79.79 MM
- NET PROFIT(HY) At SEK 53.66 MM has Grown at -32.33%
- ROCE(HY) Lowest at 1.47%
4
With ROE of 2.59%, it has a fair valuation with a 1.02 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -76.13%, its profits have fallen by -43.6%
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -76.13% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Surgical Science Sweden AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Surgical Science Sweden AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Surgical Science Sweden AB
-76.13%
-0.97
80.41%
OMX Stockholm 30
10.97%
0.59
18.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
56.77%
EBIT Growth (5y)
44.68%
EBIT to Interest (avg)
47.45
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.20
Tax Ratio
20.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.57%
ROE (avg)
4.01%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
1.02
EV to EBIT
25.80
EV to EBITDA
17.42
EV to Capital Employed
1.02
EV to Sales
3.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.95%
ROE (Latest)
2.59%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET SALES(Q)
Highest at SEK 268.85 MM
OPERATING PROFIT(Q)
Highest at SEK 70.95 MM
OPERATING PROFIT MARGIN(Q)
Highest at 26.39 %
NET PROFIT(Q)
At SEK 33.26 MM has Grown at 49.65%
-12What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at SEK 79.79 MM
NET PROFIT(HY)
At SEK 53.66 MM has Grown at -32.33%
ROCE(HY)
Lowest at 1.47%
RAW MATERIAL COST(Y)
Grown by 6.08% (YoY
Here's what is working for Surgical Science Sweden AB
Net Sales
Highest at SEK 268.85 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Operating Profit
Highest at SEK 70.95 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (SEK MM)
Operating Profit Margin
Highest at 26.39 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
At SEK 33.26 MM has Grown at 49.65%
over average net sales of the previous four periods of SEK 22.22 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
Depreciation
Highest at SEK 23.95 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (SEK MM)
Here's what is not working for Surgical Science Sweden AB
Operating Cash Flow
Lowest at SEK 79.79 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (SEK MM)
Raw Material Cost
Grown by 6.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
